{"product_id":"fosunpharma-business-model-canvas","title":"Fosun Pharma Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas: Strategic blueprint for a diversified pharma R\u0026amp;D and distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Fosun Pharma’s business model with our Business Model Canvas: three to five concise sentences reveal how it creates value across R\u0026amp;D, manufacturing, and distribution while leveraging partnerships and diversified revenue streams. Ideal for investors, consultants, and entrepreneurs—download the complete, editable Word \u0026amp; Excel files to benchmark strategies and seize opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal pharma and biotech co-development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborate with multinational and innovative biotechs for licensing-in\/out and co-development of oncology, immunology, and metabolic assets to share clinical risk and accelerate access to novel modalities. Global oncology market size was about US$223 billion in 2024, underscoring upside from expanding indications and complementary pipelines. Structure deals with milestones, co-promotion, regional rights, and technology transfer to optimize market entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and research institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartner with universities, research hospitals and key labs for early discovery, translational research and biomarker development to feed Fosun Pharma’s pipeline. Joint labs and sponsored research accelerate proof-of-concept and enable access to cutting-edge science and talent. Publication and data-sharing bolster credibility in priority therapeutic areas. These academic partnerships are central to translational success and portfolio de-risking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs, CMOs, and CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFosun Pharma leverages CROs, CMOs and CDMOs for clinical ops, specialized manufacturing and rapid scale-up, balancing in-house GMP sites with outsourced flexibility to control costs and timelines. In 2024 the global CRO market was ~USD 69bn, enabling multi-country trials and real-world evidence collection. Rigorous vendor qualification and QA audits ensure GMP compliance and product quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, healthcare systems, and KOL networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cphospitals healthcare systems and kol networks form strategic alliances to run clinical trials secure formulary inclusion drive guideline adoption in fosun leverages these ties scale evidence generation brand trust across china select global markets. engaging kols supports physician education real-world data collection while co-developing integrated patient pathways devices diagnostics outcome-based contracts aligns with expanding value-based care pilots such reported major markets by\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAlliances: clinical trials, formulary, guidelines\u003c\/li\u003e\n\u003cli\u003eKOLs: education, evidence, trust\u003c\/li\u003e\n\u003cli\u003eCo-development: drug+device+diagnostic pathways\u003c\/li\u003e\n\u003cli\u003eValue alignment: outcome-based initiatives (500+ contracts in 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phospitals\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors, retail chains, and digital platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartner with national and provincial distributors covering all 31 provincial-level regions, pharmacy chains, and major e-commerce players to maximize reach and channel efficiency; leverage 2024 digital sales growth (~25% YoY in China online pharma) to scale OTC and devices. Optimize inventory turnover and cold-chain reliability to cut spoilage and improve margins. Collaborate with B2B hospital procurement platforms and use data partnerships to refine demand forecasting.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNational\/provincial distributors: 31 regions\u003c\/li\u003e\n\u003cli\u003eChannel mix: B2B hospital platforms + B2C e-commerce\u003c\/li\u003e\n\u003cli\u003eFocus: inventory turnover, cold-chain reliability\u003c\/li\u003e\n\u003cli\u003eData: demand forecasting via retail\/e-commerce feeds\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlliances scale oncology: \u003cstrong\u003eUS$223bn\u003c\/strong\u003e; CROs and China e-pharma surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with biotechs accelerate oncology\/immunology assets and share clinical risk; global oncology market ~US$223bn in 2024. CRO\/CMO partnerships enable trials and scale—global CRO market ~US$69bn in 2024. Distributor and e-commerce ties expand reach; China online pharma grew ~25% YoY in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner type\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotechs\u003c\/td\u003e\n\u003ctd\u003eCo-dev\/licensing\u003c\/td\u003e\n\u003ctd\u003eOncology US$223bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CMO\u003c\/td\u003e\n\u003ctd\u003eTrials \u0026amp; scale\u003c\/td\u003e\n\u003ctd\u003eMarket US$69bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\/e‑commerce\u003c\/td\u003e\n\u003ctd\u003eChannel \u0026amp; reach\u003c\/td\u003e\n\u003ctd\u003eOnline +25% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Fosun Pharma outlining its 9 blocks—customer segments, value propositions (R\u0026amp;D-driven drugs, generics, healthcare services), channels (hospital, retail, digital), key partners, resources, activities, revenue streams and cost structure—highlighting diversified healthcare ecosystem, M\u0026amp;A-driven growth, partnerships and competitive advantages to inform investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Fosun Pharma’s business model with editable cells, condensing R\u0026amp;D, manufacturing, go-to-market and partnership levers into a one-page snapshot to relieve analysis bottlenecks. Perfect for teams to save hours formatting, compare scenarios and share insights for faster strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative and generic R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFosun Pharma (600196.SH) advances discovery through preclinical and clinical programs in oncology, immunology, and metabolic diseases, leveraging partnerships and internal platforms to accelerate candidates into IND and NDA stages.\u003c\/p\u003e\n\u003cp\u003eThe company manages ANDA filings and lifecycle strategies for generics and biosimilars while prioritizing differentiated formulations and combination therapies to protect market share.\u003c\/p\u003e\n\u003cp\u003eFosun maintains a regular IND\/NDA submission cadence supported by integrated R\u0026amp;D and regulatory teams to shorten development timelines and enhance portfolio value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing and quality management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperate multi-site GMP plants across small molecules, biologics and devices\/diagnostics, enforcing QA\/QC systems aligned with NMPA, FDA and EMA standards; deploy continuous improvement and process analytical technologies for yield and quality gains; secure supply via dual-sourcing and structured tech transfer to minimize disruption and accelerate scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory affairs and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory affairs and market access lead Fosun Pharmas global filings, variations and pharmacovigilance operations to secure approvals across markets while maintaining HKEX listing 2196 visibility.\u003c\/p\u003e\n\u003cp\u003eTeams navigate NRDL inclusion, provincial tenders and volume-based procurement dynamics to optimize formulary placement and public reimbursement pathways.\u003c\/p\u003e\n\u003cp\u003eHEOR dossiers and pricing strategies are developed to support value propositions, while coordinated post-marketing surveillance and risk management plans ensure safety and compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial execution and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDeploy specialized salesforces and KAM teams into hospitals and payer networks to secure formulary access and drive hospital tenders; medical affairs runs scientific engagement, CME and publication strategies to support uptake. Brand planning and omni-channel promotion operate within compliance frameworks, while patient programs target adherence—WHO estimates medication adherence around 50%, and support initiatives can boost adherence by 10–20%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSalesforce\/KAM deployment to hospitals and payers\u003c\/li\u003e\n\u003cli\u003eScientific engagement, CME, publications\u003c\/li\u003e\n\u003cli\u003eBrand planning and omni-channel compliant promotion\u003c\/li\u003e\n\u003cli\u003ePatient support programs to improve adherence (~10–20%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness development and international expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFosun Pharma sources, evaluates and negotiates licensing deals, JVs and M\u0026amp;A to broaden therapeutic portfolios and address regional needs, targeting high-growth segments within the ~USD 1.6 trillion 2024 global pharmaceutical market. It localizes portfolios for emerging markets while scaling successful assets in developed markets, builds regional hubs and distribution footprints, and integrates acquisitions to capture manufacturing, R\u0026amp;D and commercial synergies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing\/JV\/M\u0026amp;A sourcing\u003c\/li\u003e\n\u003cli\u003ePortfolio localization for emerging markets\u003c\/li\u003e\n\u003cli\u003eScale-up in developed markets\u003c\/li\u003e\n\u003cli\u003eRegional hubs \u0026amp; distribution\u003c\/li\u003e\n\u003cli\u003ePost-merger integration to capture synergies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D to IND\/NDA, GMP scale-up and commercial push in \u003cstrong\u003eUSD 1.6T\u003c\/strong\u003e market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D advances oncology, immunology and metabolic candidates through preclinical to IND\/NDA with partnership acceleration; multi-site GMP manufacturing for small molecules, biologics and devices ensures scale and QA\/QC; regulatory, HEOR and market-access teams drive NRDL\/tender strategies and pharmacovigilance; commercial KAMs, omni-channel marketing and M\u0026amp;A\/licensing expand regional footprints—global pharma market ~USD 1.6T (2024), HKEX 2196.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D focus\u003c\/td\u003e\n\u003ctd\u003eOncology\/Immunology\/Metabolic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eMulti-site GMP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003eUSD 1.6T (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eListing\u003c\/td\u003e\n\u003ctd\u003eHKEX 2196\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed is the exact Fosun Pharma Business Model Canvas you'll receive—no mockups or samples. Upon purchase you'll download this same complete, editable file ready for presentation, analysis, and customization. All pages, content and formatting match the preview with no hidden sections or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161622851961,"sku":"fosunpharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/fosunpharma-business-model-canvas.png?v=1762695384","url":"https:\/\/portersfiveforce.com\/products\/fosunpharma-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}